REDVET - Revista electrónica de Veterinaria - ISSN 1695-7504
Vol 25, No. 1 (2024)
http://www.veterinaria.org

Ai In Pharmaceutical Innovation: A Review Of Drug Discovery And Clinical Trial Integration

Yashaswini N[1*], Ramesh Aravind S[2], Pavithra R[3], Anant Uday Naik[4]

[1*,2,3,4]Department of Pharmacy Practice, East West College of Pharmacy, Bengaluru, Karnataka, India

ABSTRACT
Artificial Intelligence has revolutionized the process of drug discovery and improved clinical trials, which lead to the reduction of time and cost. Our review highlights the role of Prescription AI in the evolution of drug development processes. The first quartile discusses QSAR modeling and binding free energy molecular docking, coupled with how these methods can be improved with AI. They are capable of predicting molecular interactions at astonishing levels of accuracy. Identifying and validating more effective drug targets with the help of AI. Utilizing machine learning and multi-omics approaches to discover novel therapies. It summarizes committee-overseen AI-driven molecular engineered drugs. For instance, drugs' ADMET properties help design and screen lead drug candidates. AI has had a similar impact on all lines of clinical trials in consolidation. From the processes of patient specification & categorization, to novel visualization techniques. Moreover, there exists a paradigm of drug-device combinations which allows for novel drug development strategies. Untapped areas of marketed drugs and synergies in treatment may enhance efficacy. Data deficiencies, bias in algorithms and regulatory compliant mechanisms are barriers that must be addressed. This study emphasizes the efforts made to resolve the issues of ethical transparency. The review emphasises principles to stem the abuse of AI in pharmaceutical advancement. In this review, The AI is embedded across all phases of drug development process. From the inception of the drug to the testing of it on humans so as to the impact of AI on the future of healthcare. It creates a foundation for more advanced research and partnerships in pharmaceutical AI.

KEYWORDS: Artificial Intelligence (AI), Drug Discovery, Clinical Trials, Molecular Design, Target Validation, Pharmaceutical Innovation.

INTRODUCTION

This review delves into the significant changes that artificial intelligence (AI) brings to drug discovery, focusing particularly on its enhancement of trials.
For complex diseases like cancer or during pandemics such as COVID-19, effective treatment often requires the use of multiple drugs in combination to address both the progression and underlying mechanisms of the disease. Despite significant advancements in the pharmaceutical industry, the process of drug development has remained time-consuming and expensive. To accelerate this process, numerous computational algorithms have been proposed, which offers a more efficient and cost-effective approach to drug discovery. AI tools help streamline various stages of development, potentially reducing the time and resources required to bring new therapies to market [37].

QSAR (Quantitative Structure Activity Relationship) and Molecular Docking

QSAR models use Machine learning (ML) and Deep learning (DL) algorithms to predict the biological activity of molecules based on their chemical structure.
Machine learning algorithms analyze vast data to find hidden patterns, accelerates the discovery of new bioactive compounds with minimal side effects compared to traditional methods. ML also aids in predicting toxicity based on extensive databases of toxic and non-toxic compounds.
Deep learning models, based on datasets of known drugs, accurately predict the biological activity of new compounds, rapidly generate new drugs efficiently with desirable properties like solubility and effectiveness and also identifies drug-drug interactions.
Molecular docking involves the use of algorithms to predict the binding of molecule to protein target [38].
ML and DL have notably redefined various phases of the drug development journey, from identifying and confirming potential targets to refining clinical trials [1], [2], [3]. These advancements hold the promise of streamlining the drug discovery process, lowering expenses, and enhancing patient outcomes.
The review consolidates recent findings to offer a comprehensive examination of AI's impact on drug development. It shows key milestones while also addressing the ongoing limitations and challenges. In particular, it explores AI's role at each stage of the process, including early target identification, drug formulation, and the planning, implementation, and evaluation of clinical trials. These challenges impede the broader adoption of promising AI methodologies in clinical practice and limit the ability to fully leverage AI's potential to accelerate drug discovery and enhance patient outcomes.
While AI offers the promise of faster, more cost-effective, and efficient drug development [31], [32], achieving these benefits requires overcoming significant barriers and addressing critical knowledge gaps. Furthermore, this review discusses the ethical and regulatory challenges associated with integrating AI into drug discovery and development,

explaining the complexities involved in embracing such innovative technologies in this essential field that must be resolved to unlock the full capabilities of AI in this transformative field.

Table 1: Applications of Deep learning (DL) in drug discovery

Application Area	Description
Drug-Target Interactions (DTIs)	Deep learning models predict how drugs interact with specific biological targets, identifying new drug candidates and uncovering unknown mechanisms of action.
Drug-Drug Similarity Interactions (DDIs)	DL techniques assess interactions between drugs, helping to identify harmful combinations and optimize treatment regimens.
Drug Sensitivity and Responsiveness	Deep learning predicts how individual patients will respond to drugs based on genetic makeup and other factors, enabling personalized treatment plans.
Drug Side Effect Predictions	DL models analyze clinical and molecular data to predict potential side effects of drugs, allowing for earlier intervention and safer drug development.

AI in Drug Target Identification and Validation

The identification and validation of drug targets are critical components in the stages of drug development. Yet, conventional techniques in this area tend to be slow, labor-intensive, and often come with high failure rates. Artificial intelligence (AI) presents a groundbreaking alternative, facilitating quicker and more precise identification and validation of these drug targets.

How AI Enhances Target Identification

AI, especially through machine learning (ML) and deep learning (DL) technologies, is transforming the process of identifying drug targets by examining large and complex datasets with unmatched accuracy [4], [5], [6]. These methods can analyze genomic, proteomic, transcriptomic, and clinical information to anticipate interactions between drugs and proteins while revealing potential therapeutic targets for various diseases [7].

AI's major advantage lies in its skill at detecting complex patterns and relationships within extensive datasets abilities that greatly outperform traditional techniques. For instance, AI plays a crucial role in finding new drug targets for rare genetic disorders, where standard methods often struggle. By combining genetic and clinical information from various sources, AI develops a thorough understanding of disease mechanisms, leading to the discovery of novel therapeutic targets [8]. Techniques like feature selection also improve this process by highlighting the most pertinent data points, simplifying complexities, and boosting the overall efficiency of target identification.

The Power of Multi-Omics Integration

One of the most significant contributions of AI in drug target identification is its capability to integrate multi-omics data. By concurrently analysing genomic, transcriptomic, proteomic, and metabolomic information, AI delivers a comprehensive overview of disease mechanisms. This all-encompassing approach can pinpoint potential drug targets that might otherwise be missed when looking at individual data types separately.

This unified perspective is especially crucial in addressing complex diseases, where multiple biological pathways interact. AI's ability to merge insights from various datasets allows researchers to discover new targets that resonate more closely with the underlying biology of such diseases, thereby increasing the chances of therapeutic success.

In general, AI has reformed identification by enabling the analysis of extensive datasets, integrating different data types, and revealing previously obscured disease mechanisms, thus providing more effective and efficient strategies for drug development.

AI-Driven Target Validation

Target validation is a crucial step in drug development, involving the confirmation that a proposed drug target plays a significant role in the disease process and that modulating its activity can yield therapeutic benefits. Traditionally, this process requires extensive experimental validation, which is both time-consuming and costly. However, AI is increasingly being utilized to streamline and enhance target validation, offering more efficient and cost-effective approaches [5].

AI-powered simulations are transforming the validation process by predicting the therapeutic profile of potential drug candidates based on their molecular properties and interactions with the target [4]. These simulations reduce the dependency on labor-intensive experimental methods, enabling faster progression through the drug development pipeline [9]. Using AI models, researchers can evaluate critical aspects of drug-target interactions, such as binding affinity, therapeutic efficacy, and potential off-target effects. This prioritization of the most promising candidates helps minimize the resources required for further testing, significantly cutting both costs and timelines.

In addition to predictive modeling, AI also plays a vital role in analysing data from experimental validation studies. By integrating results from *in vitro* and *in vivo* experiments, AI algorithms uncover patterns and relationships that may be overlooked by human researchers. This leads to more accurate and efficient target validation, enhancing the overall effectiveness of the drug development process.

The integration of AI-driven target validation with high-throughput screening techniques offers even greater potential. By combining the capabilities of AI with the ability to screen large libraries of compounds rapidly, researchers can identify

the most promising drug candidates for further development more effectively. This approach not only speed up the validation process but also increases the probability of discovering successful therapeutic interventions.

AI in Drug Design and Optimization

After identifying and validating potential drug targets, the next critical step in the drug discovery process is designing and optimizing molecules that effectively interact with these targets. Traditionally, this has been a time-consuming and ceaseless process involving substantial trial and error. However, AI is transfiguring drug design by introducing innovative and efficient methodologies.

AI-Assisted Molecular Design

AI is transforming how novel drug molecules are designed by enabling the creation of compounds with desired properties, such as high potency, selectivity, and improved pharmacokinetics [10], [7]. A key innovation in this space is the use of generative models, which can either design new molecules from scratch (*de novo*) or optimize existing lead compounds [4], [11].

Generative models excel at exploring vast chemical spaces, identifying potential molecules that traditional methods might overlook [6]. By learning from extensive datasets of known compounds and their associated properties, these models can generate new molecules tailored to specific therapeutic needs. This capability dramatically accelerates the drug design process, enabling researchers to identify innovative drug candidates with enhanced efficacy and safety profiles.

In addition to discovering novel compounds, AI-assisted molecular design can refine and optimize existing lead molecules. This includes improving critical characteristics such as bioavailability, stability, and target selectivity, while minimizing potential toxicity. By reducing the reliance on labor-intensive experimental approaches, AI significantly streamlines the optimization phase, facilitating for the development of safer and more effective therapies. However, evaluating generative models presents significant challenges. Conventional metrics may not effectively capture the quality and novelty of the molecules they produce, highlighting the need for the development of new assessment methodologies [33].

Predicting Drug Properties and ADMET

The anticipation of drug properties, including absorption, distribution, metabolism, excretion, and toxicity (ADMET), plays a vital role in drug development [4], [12]. Accurate ADMET predictions help identify potential toxicity concerns early in the process, which can save both time and resources [13].

AI algorithms are being increasingly utilized to predict these properties by analysing the molecular structure and other relevant characteristics of drug candidates. This approach can reduce the need for expensive in vivo testing, thus accelerating the drug development process and minimizing the risk of failures at later stages [10].

By integrating various data sources, such as experimental data, chemical structures, and biological activity, AI models can deliver more accurate and reliable ADMET predictions. This comprehensive assessment allows for better-informed decisions about the further development of drug candidates.

AI in Clinical Trial Design and Optimization

Clinical trials are a vital but costly stage in drug development. AI is revolutionizing this phase by offering ways to enhance efficiency, reduce costs, and increase the likelihood of trial success. AI's advanced data analytics helps to optimize trial design, improve patient recruitment, and predict outcomes more accurately, leading to more effective and streamlined clinical trials.

AI-Driven Patient Selection and Stratification

AI has the potential to greatly enhance patient selection for clinical trials by identifying individuals who will benefit most from the specific interventions [14], [15].

This process involves analysing a range of patient data, including genomic profile, medical history, lifestyle factors, and other relevant details to pinpoint suitable candidates [16].

AI algorithms can recognize patterns and relationships within this data that might be overlooked by human researchers, leading to more precise patient selection and stratification. By focusing on patients who are more likely to respond to the treatment and minimizing those who might not benefit, this approach makes clinical trials more efficient and effective, conserving resources and speeding up the drug development process.

In the context of personalized medicine, AI-driven patient stratification is especially valuable. By identifying groups of patients who may respond differently to the same treatment, AI can assist in tailoring therapeutic strategies to each patient's needs, thus improving treatment outcomes. This approach is essential for developing effective therapies for complex diseases, where standardized treatments may not be appropriate.

AI-Powered Trial Design and Monitoring

AI is also revolutionizing the design and implementation of clinical trials [14], [17]. It is being used to predict trial outcomes, determine optimal sample sizes, and customize treatment protocols. AI systems can remotely monitor patients,

gathering real-time data on their health status and treatment responses [15]. This enhances patient adherence and reduces the likelihood of adverse events [18]. By analysing large volumes of clinical trial data, AI can identify key factors that contribute to a trial's success or failure, helping to refine future trial designs and improve their chances of success. Additionally, AI can automate various trial management tasks such as patient recruitment, data entry, and analysis, allowing researchers to focus on other critical areas. This can result in considerable cost savings and expedite the overall clinical trial process.

AI in Drug Repurposing and Combination Therapy

AI is transforming not just the discovery of new drugs but also the repurposing of existing drugs and the optimization of combination therapies.

Discovering Novel indications for established drugs

AI can greatly speed up the process of drug repurposing by unveiling potential new applications for existing medications [3], [19]. This involves analyzing extensive datasets of drug-target interactions and clinical outcomes to identify molecules that could be effective against different diseases [13]. AI algorithms are able to detect patterns and connections between drug molecules and their impact on various biological systems, enabling the discovery of new therapeutic uses. This approach not only shortens the drug discovery timeline but also reduces the time and resources needed to introduce new treatments to the market [20]. Repurposing existing drugs holds great promise for treating rare diseases and conditions with few treatment options, and it tends to be more cost-effective than developing entirely new drugs, as it builds on existing knowledge and data.

Optimizing Combination Therapies

For many diseases, combination therapies are necessary to achieve the best possible treatment outcomes. AI can enhance the optimization of these therapies by predicting how different drugs will interact, identifying whether their effects will be synergistic or antagonistic [19]. This can result in more effective treatments with fewer side effects [21]. AI algorithms can process vast datasets of drug interactions to spot the most beneficial drug combinations for specific diseases [13]. This approach helps create safer and more effective treatments, reducing adverse events and improving patient outcomes. Additionally, AI can personalize combination therapies by tailoring treatment regimens to specific patients based on their unique characteristics and needs, further enhancing treatment effectiveness and minimizing the risk of side effects.

Table 2: AI applications in the stages of drug discovery

Stages of Drug Discovery	AI Applications	Citations
Target Identification	Predictive modeling, machine learning, deep learning, multi-omics data integration	[5], [6], [8], [7]
Drug Design	Generative models, molecular dynamics simulations, property prediction, ADMET prediction	[4], [10], [7], [12], [13]
Clinical Trials	Patient selection, trial design optimization, real-time monitoring, patient stratification	[14], [16], [15], [18]
Drug Repurposing	Data analysis, predictive modeling, target identification	[3], [19], [13]
Combination Therapy	Synergy prediction, drug interaction analysis	[19], [13], [21]

Challenges and Ethical Considerations

While AI offers tremendous potential in drug discovery, several challenges and ethical issues need to be addressed to ensure its responsible and beneficial use.

Data Availability and Quality

AI's potential in drug discovery is contingent upon the availability and quality of data [3], [6], [7]. However, obtaining and integrating diverse datasets can present significant challenges, and issues with data quality can affect the accuracy and reliability of AI models [22], [23]. To improve outcomes of AI-driven drug discovery, data standardization and harmonization are essential [1]. Without consistent data formats and high-quality data, the development and application of AI models can be severely hindered. Therefore, it is critical to establish strong data integration and quality control processes to ensure the trustworthiness and broad applicability of AI-generated results.

Another challenge is the availability of sufficient data, especially for rare diseases or conditions where limited information exists. To address this, strategies for augmenting existing datasets and generating synthetic data are necessary to improve the performance of AI models.

Algorithmic Bias and Transparency

AI models can reflect and perpetuate biases present in their training data sets, potentially leading to inaccurate or unfair results [24]. Ensuring transparency in AI models and reducing bias are crucial steps in building trustworthy systems [25]. The lack of transparency can make it difficult to understand how AI models make decisions, raising concerns about their

fairness and reliability. This highlights the need for explainable AI (XAI), which seeks to make AI decision making more transparent and accessible.
Additionally, biases in training data can result in AI models that unfairly discriminate against specific patient groups. This is particularly concerning in drug development, where AI models are used to determine which patients should receive certain treatments. To address algorithmic bias it is essential to exercise caution and vigilance during data collection and model development along with continuous monitoring to identify and mitigate potential biases.

Ethical and Regulatory Concerns
The incorporation of AI in drug discovery raises several ethical and regulatory concerns [1], [2], [25]. Key concerns include data privacy, the potential misuse of AI algorithms, and the need for appropriate regulatory frameworks to govern AI-driven therapies. Patient data is often used in AI models, raising critical privacy issues. It is imperative to ensure that patient data is handled ethically and responsibly, with sturdy measures in place to protect confidentiality. Another ethical issue is the possibility of AI being used to discriminate against certain patient groups. To address this, strong regulatory frameworks are necessary to ensure that AI-driven therapies are safe, effective, and ethically deployed [23]. Collaboration between researchers, regulators, and ethicists is vital in creating guidelines and regulations that balance innovation with safety.
Furthermore, the growing reliance on AI in drug discovery raises concerns about the displacement of human expertise and the potential impact on the workforce. To prevent job losses and ensure the continued quality of research, there is a need for proactive workforce development. This includes providing training and support to help researchers adapt to the changes AI brings to the field.

Table 3: Examples of successful AI integrated drug discovery

1. Gupta, R., et al. achieved a breakthrough in leveraging AI to identify innovative cancer compounds. They trained a DL algorithm on a large dataset of cancer-related compounds, yielding novel compounds with immense potential. This demonstrates the efficacy of AI in discovering new therapeutic candidates. [39].
2. AI/ML-guided CNS drug discovery, focusing on blood–brain barrier permeability prediction and implementation into therapeutic discovery for neurological diseases [40].
3. In the latest research, researchers utilized machine learning algorithms to identify new inhibitors of beta-secretase (BACE1), a key enzyme implicated in Alzheimer's disease escalation. Specifically, they developed multi-target, ligand-based 2D-QSAR models to evaluate the inhibitory potential of various N-benzyl piperidine derivatives. These compounds demonstrated dual inhibitory activity, targeting both AChE and BACE1, highlighting their promise as multitarget-directed agents for Alzheimer's therapy [41].
4. Numerous other studies [42, 43, 44, 45] demonstrate how AI-powered approaches are pioneering pharmaceutical innovation by speeding up the process and facilitating the design of more effective therapies.

CONCLUSION
AI is reinventing the landscape of drug discovery and clinical trials, offering the promise of accelerating the development of innovative therapies and enhancing patient outcomes. While significant progress has been made in various aspects of drug development, challenges such as data availability, algorithmic bias, and ethical concerns still pose barriers to fully realizing AI's potential in healthcare. Overcoming these obstacles will be crucial for unlocking the full transformative power of AI in drug discovery.

To ensure AI is integrated responsibly and beneficially into the drug development process, continued research and collaboration across discipline - spanning science, medicine, ethics, and regulation will be essential [26], [27], [28]. As AI continues to evolve, its role in drug discovery will undoubtedly expand, reshaping every stage of the process, from molecule design to clinical trials.

The integration of AI into drug discovery offers immense potential to speed up the development of new treatments and improve patient outcomes [34], [35]. However, significant gaps remain, particularly in areas such as data bias, model interpretability, ethical considerations, and the establishment of regulatory frameworks. To truly harness AI's transformative capabilities, these gaps must be addressed through rigorous research, the creation of resilient and ethical AI methodologies, and close interdisciplinary collaboration. This will ensure that AI-driven drug discovery is not only effective but also equitable, offering new therapies to a broader range of patients.

The future of drug discovery will be shaped by how well these challenges are navigated sustaining innovation while ensuring responsible use of AI technologies [29], [30]. Although the path forward is complex, the potential rewards quicker drug development, more effective treatments, and improved patient outcomes make the pursuit of AI-driven drug discovery a promising and worthwhile endeavour. With continued research, collaboration, and ethical vigilance, AI can unlock its full potential in revolutionizing drug discovery and healthcare as a whole.
Author Disclosure: The authors have no conflicts to disclose.

REFERENCES

1. Huang, D., Yang, M., Wen, X., Xia, S., & Yuan, B. (2024). AI-Driven drug discovery: Accelerating the development of novel therapeutics in biopharmaceuticals. International Medical Science Research Journal, 4(8). https://doi.org/10.51594/imsrj.v4i8.1458
2. Ejeta, B. M., Das, M. K., Das, S., Bekere, F. F., & Tayeng, D. (2024). Transformative Role of Artificial Intelligence in the Pharmaceutical Sector. Journal of Angiotherapy. https://doi.org/10.25163/angiotherapy.899933
3. Kokudeva, M., Vichev, M., Naseva, E., Miteva, D., & Velikova, T. (2024). Artificial intelligence as a tool in drug discovery and development. World Journal of Experimental Medicine, 14(3). https://doi.org/10.5493/wjem.v14.i3.96042
4. Han, R., Yoon, H., Kim, G., Lee, H., & Lee, Y. (2023). Revolutionizing Medicinal Chemistry: The Application of Artificial Intelligence (AI) in Early Drug Discovery. Pharmaceuticals, 16(9). https://doi.org/10.3390/ph16091259
5. Wenteler, A., Cabrera, C. P., Wei, W., Neduva, V., & Barnes, M. R. (2024). AI approaches for the discovery and validation of drug targets. None. https://doi.org/10.1017/pcm.2024.4
6. Alanazi, A. A. A., Al Fahad, A. I. A., Almorshed, A. S. A., Alrbian, A. A. M., Alnughaymishi, A. A. S., Al-Mutairi, N. H. B., & Alajmi, A. A. (2022). Artificial intelligence in drug discovery: Current applications and future directions. International Journal of Health Sciences, 6(10). https://doi.org/10.53730/ijhs.v6ns10.15290
7. Deng, J., Yang, Z., Samaras, D., & Wang, F. (2021). Artificial Intelligence in Drug Discovery: Applications and Techniques. None. https://doi.org/10.1093/bib/bbab430
8. T, S., Kaliappan, S., Ali, H., & Vijay Kumar, B. (2024). AI - Driven Drug Discovery and Therapeutic Target Identification for Rare Genetic Diseases. None. https://doi.org/10.1109/ASSIC60049.2024.10507989
9. Matsuzaka, Y., & Yashiro, R. (2022). Applications of Deep Learning for Drug Discovery Systems with BigData. BioMedInformatics, 2(4). https://doi.org/10.3390/biomedinformatics2040039
10. Deepthimahanthi, Y. P., Balu, P., Shing, W. L., Krishnan, K., Manjunathan, J., Ashokkumar, K., Jayanthi, M., Suganthi, M., & Abirami, G. (2023). AI-Based Drug Design: Revolutionizing Drug Discovery through in Silico Analysis. None. https://doi.org/10.61453/intij.202356
11. McGibbon, M., Shave, S., Dong, J., Gao, Y., Houston, D. R., Xie, J., Yang, Y., Schwaller, P., & Blay, V. (2023). From intuition to AI: Evolution of small molecule representations in drug discovery. None. https://doi.org/10.1093/bib/bbad422
12. Walters, W., & Barzilay, R. (2021). Critical assessment of AI in drug discovery. Expert Opinion on Drug Discovery, 16(2), 91–101. https://doi.org/10.1080/17460441.2021.1915982
13. Vinayak, N. V., Lingolu, D., Kumari, D., & Kumar, P. (2024). Evaluating the Impact of AI and ML on Modern Drug Discovery. None. https://doi.org/10.69613/8tckqp18
14. Harrer, S., Shah, P., Antony, B., & Hu, J. (2019). Artificial Intelligence for Clinical Trial Design. Elsevier BV. https://doi.org/10.1016/j.tips.2019.05.005
15. Serrano, D., Luciano, F. C., Anaya, B. J., Ongoren, B., Kara, A., Molina, G., Ramirez, B. I., Snchez-Guirales, S. A., Simon, J. A., Tomietto, G., Rapti, C., Ruiz, H. K., Rawat, S., Kumar, D., & Lalatsa, A. (2024). Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine. Pharmaceutics, 16(10). https://doi.org/10.3390/pharmaceutics16101328
16. Mohapatra, M., Sahu, C., & Mohapatra, S. (2024). Trends of Artificial Intelligence (AI) Use in Drug Targets, Discovery and Development: Current Status and Future Perspectives. Current Drug Targets. https://doi.org/10.2174/0113894501322734241008163304
17. Shaheen, M. Y. (2021). Applications of Artificial Intelligence (AI) in healthcare: A review. None. https://doi.org/10.14293/s2199-1006.1.sor-.ppvry8k.v1
18. Chen, D., Cao, C., Kloosterman, R., Parsa, R., & Raman, S. (2024). Trial Factors Associated With Completion of Clinical Trials Evaluating AI: Retrospective Case-Control Study. Journal of Medical Internet Research. https://doi.org/10.2196/58578
19. Visan, A., & Negu, I. (2024). Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery. None. https://doi.org/10.3390/life14020233
20. Dhudum, R., Ganeshpurkar, A., & Pawar, A. (2024). Revolutionizing Drug Discovery: A Comprehensive Review of AI Applications. None. https://doi.org/10.3390/ddc3010009
21. Sumathi, S., Suganya, K., Swathi, K., Sudha, B., Poornima, A., Varghese, C. A., & Aswathy, R. (2023). A Review on Deep Learning-Driven Drug Discovery: Strategies, Tools, and Applications. Current Pharmaceutical Design. https://doi.org/10.2174/1381612829666230412084137
22. Ashiwaju, B., Orikpete, O., & Uzougbo, C. (2023). The intersection of artificial intelligence and big data in drug discovery: A review of current trends and future implications. Matrix Science Pharma. https://doi.org/10.4103/mtsp.mtsp_14_23
23. 23. Patil, P., Nrip, N. K., Hajare, A., Hajare, D. A., Patil, M. K., Kanthe, R., & Gaikwad, A. T. (2023). Artificial Intelligence and Tools in Pharmaceuticals: An Overview. Research Journal of Pharmacy and Technology. https://doi.org/10.52711/0974-360x.2023.00341

24. Protrka, N., & Abazi, B. (2024). Artificial Intelligence in Health Care: Various Applications. International Convention on Information and Communication Technology, Electronics and Microelectronics. https://doi.org/10.1109/MIPRO60963.2024.10569971
25. Blanco-González, A., Cabeza, A., Seco-González, A., Conde-Torres, D., Antelo-Riveiro, P., Piñeiro, Á., & García-Fandiño, R. (2023). The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. Multidisciplinary Digital Publishing Institute. https://doi.org/10.3390/ph16060891
26. Hasselgren, C., & Oprea, T. I. (2023). Artificial Intelligence for Drug Discovery: Are We There Yet? Annual Reviews. https://doi.org/10.1146/annurev-pharmtox-040323-040828
27. Niazi, S. K. (2023). The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives. Drug Design, Development, and Therapy. https://doi.org/10.2147/DDDT.S424991
28. Usmani, U. A., & Usmani, M. U. (2023). AI-Driven Biomedical and Health Informatics: Harnessing Artificial Intelligence for Improved Healthcare Solutions. None. https://doi.org/10.1109/INCOFT60753.2023.10425780
29. Nuthakki, S. K., & Siddhartha, K. (2023). AI and The Future of Medicine: Pioneering Drug Discovery with Language Models. International Journal of Science and Research (IJSR). https://doi.org/10.21275/sr24304173757
30. Singh, S., Kumar, R., Payra, S., & Singh, S. K. (2023). Artificial Intelligence and Machine Learning in Pharmacological Research: Bridging the Gap Between Data and Drug Discovery. Cureus, Inc.. https://doi.org/10.7759/cureus.44359
31. Gabashvili, A. U., & Irene, S. (2023). Artificial Intelligence in Biomedicine: Systematic Review. medRxiv. https://doi.org/10.1101/2023.07.23.23292672
32. Kokudeva, M., Vichev, M., Naseva, E., Miteva, D., & Velikova, T. (2024). Artificial intelligence as a tool in drug discovery and development. World Journal of Experimental Medicine, 14(3), 960–976. https://doi.org/10.5493/wjem.v14.i3.96042
33. Burri, S. R., Diallo, M. Y., Sharma, L., & Dutt, V. (2023). AI-Driven Drug Discovery: Unravelling the Potential of Generative Adversarial Networks (GANs) in Pharmaceutical Research. None. https://doi.org/10.1109/ICTACS59847.2023.10390116
34. Alanazi, A. A. A., Al Fahad, A. I. A., Almorshed, A. S. A., Alrbian, A. A. M., Alnughaymishi, A. A. S., Al-Mutairi, N. H. B., Alajmi, A. A., & Al Otaibi, S. G. (2022). Artificial intelligence in drug discovery: Current applications and future directions. International Journal of Health Sciences, 6(10), 152–163. https://doi.org/10.53730/ijhs.v6ns10.15290
35. Zeb, S., Fnu, N., Abbasi, N., & Fahad, M. (2024). AI in Healthcare: Revolutionizing Diagnosis and Therapy. None. https://doi.org/10.47709/ijmdsa.v3i3.4546
36. Askr, H., Elgeldawi, E., & Ella, A. E. (2023). Deep learning in drug discovery: An integrative review and future challenges. Artificial Intelligence Review, 56, 5975–6037. https://doi.org/10.1007/s10462-022-10306-13
37. T., B., & Mansoor, Z. J. (2021). Using drug–drug and protein-protein similarities as feature vectors for drug–target binding prediction. Chemometrics and Intelligent Laboratory Systems, 217, 104405. https://doi.org/10.1016/j.chemolab.2021.104405
38. Tropsha, A., Isayev, O., Varnek, A., Schneider, G., & Cherkasov, A. (2024). Integrating QSAR modeling and deep learning in drug discovery: The emergence of deep QSAR. Nature Reviews Drug Discovery, 23(2), 141–155. https://doi.org/10.1038/s41573-023-00832-0
39. Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021). Artificial intelligence to deep learning: Machine intelligence approach for drug discovery. Molecular Diversity, 25(3), 1315–1360. https://doi.org/10.1007/s11030-021-10217
40. Vatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M. M., & Zhang, B. (2021). Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. Medical Research Reviews, 41(5), 1427–1473. https://doi.org/10.1002/med.21764
41. Dhamodharan, G., & Mohan, C. G. (2022). Machine learning models for predicting the activity of AChE and BACE1 dual inhibitors for the treatment of Alzheimer's disease. Molecular Diversity, 26(2), 175–183. https://doi.org/10.1007/s11030-021-10282
42. Zhou, Y., Wang, F., Tang, J., Nussinov, R., & Cheng, F. (2020). Artificial intelligence in COVID-19 drug repurposing. The Lancet Digital Health, 2(11), e667–e676. https://doi.org/10.1016/S2589-7500(20)30192-8
43. Verma, N., Qu, X., Trozzi, F., Elsaied, M., Karki, N., Tao, Y., Zoltowski, B., Larson, E. C., & Kraka, E. (2021). Predicting potential SARS-CoV-2 drugs: In-depth drug database screening using deep neural network framework SSNet, classical virtual screening, and docking. International Journal of Molecular Sciences, 22(4), 1392. https://doi.org/10.3390/ijms22041573
44. Bung, N., Krishnan, S. R., Bulusu, G., & Roy, A. (2021). De novo design of new chemical entities for SARS-CoV-2 using artificial intelligence. Future Medicinal Chemistry, 13(6), 575–585. https://doi.org/10.4155/fmc-2020-0262
45. Lv, H., Shi, L., Berkenpas, J. W., Dao, F. Y., Zulfiqar, H., Ding, H., Zhang, Y., Yang, L., & Cao, R. (2021). Application of artificial intelligence and machine learning for COVID-19 drug discovery and vaccine design. Briefings in Bioinformatics, 22(6), bbab320. https://doi.org/10.1093/bib/bbab320